Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sayo Kobayashi is active.

Publication


Featured researches published by Sayo Kobayashi.


Journal of Gastroenterology and Hepatology | 2011

Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.

Koji Miyahara; Kazuhiro Nouso; Takeshi Tomoda; Sayo Kobayashi; Hiroaki Hagihara; Kenji Kuwaki; Junichi Toshimori; Hideki Onishi; Fusao Ikeda; Yasuhiro Miyake; Shinichiro Nakamura; Hidenori Shiraha; Akinobu Takaki; Kazuhide Yamamoto

Background and Aim:  Sorafenib, the first agent demonstrated to have efficacy to improve the survival of patients with advanced hepatocellular carcinoma (HCC), is an active multikinase inhibitor affecting angiogenesis and tumor proliferation. We analyzed cytokines related to angiogenesis or cell proliferation, and tried to determine their utility as biomarkers of sorafenib treatment effect for HCC.


PLOS ONE | 2013

Serum Glycan Markers for Evaluation of Disease Activity and Prediction of Clinical Course in Patients with Ulcerative Colitis

Koji Miyahara; Kazuhiro Nouso; Shunsuke Saito; Sakiko Hiraoka; Keita Harada; Sakuma Takahashi; Yuki Morimoto; Sayo Kobayashi; Fusao Ikeda; Yasuhiro Miyake; Hidenori Shiraha; Akinobu Takaki; Hiroyuki Okada; Maho Amano; Kazuko Hirose; Shin-Ichiro Nishimura; Kazuhide Yamamoto

Background The aims of this study were to determine the change of whole-serum N-glycan profile in ulcerative colitis (UC) patients and to investigate its clinical utility. Methods We collected serum from 75 UC patients at the time of admission and the same number of age/sex-matched healthy volunteers. Serum glycan profile was measured by comprehensive quantitative high-throughput glycome analysis and was compared with disease activity and prognosis. Results Out of 61 glycans detected, 24 were differentially expressed in UC patients. Pathway analysis demonstrated that highly sialylated multi-branched glycans and agalactosyl bi-antennary glycans were elevated in UC patients; in addition, the glycan ratio m/z 2378/1914, which also increased in UC, showed the highest Area under Receiver Operating Characteristic curve (0.923) for the diagnosis of UC. Highly sialylated multi-branched glycans and the glycan ratio m/z 2378/1914 were higher in the patients with total colitis, Clinical Activity Index >10, Mayo endoscopic score 3, or a steroid-refractory status. In particular, the glycan ratio m/z 2378/1914 (above median) was an independent prognostic factor for the need for an operation (hazard ratio, 2.67; 95% confidence interval, 1.04–7.84). Conclusions Whole-serum glycan profiles revealed that the glycan ratio m/z 2378/1914 and highly sialylated multi-branched glycans increase in UC patients, and are correlated with disease activity. The glycan ratio m/z 2378/1914 was an independent predictive factor of the prognosis of UC.


Journal of Gastroenterology and Hepatology | 2012

Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: A case control study

Takeshi Tomoda; Kazuhiro Nouso; Akiko Sakai; Mamoru Ouchida; Sayo Kobayashi; Koji Miyahara; Hideki Onishi; Shinichiro Nakamura; Kazuhide Yamamoto; Kenji Shimizu

Backgroud and Aim:  Chronic hepatitis C virus (HCV) infection is a well known risk factor for hepatocellular carcinoma (HCC). The aim of this study is to elucidate the genetic risk of development and recurrence of HCC in patients with HCV.


Journal of Gastroenterology and Hepatology | 2011

Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein

Kazuhiro Nouso; Yoshiyuki Kobayashi; Shinichiro Nakamura; Sayo Kobayashi; Hiroki Takayama; Junichi Toshimori; Kenji Kuwaki; Hiroaki Hagihara; Hideki Onishi; Yasuhiro Miyake; Fusao Ikeda; Hidenori Shiraha; Akinobu Takaki; Yoshiaki Iwasaki; Haruhiko Kobashi; Kazuhide Yamamoto

Background and Aim:  Fucosylated alpha‐fetoprotein (AFP‐L3) is known to be a marker of poor prognosis in patients with hepatocellular carcinoma (HCC). However, it has been difficult to measure AFP‐L3 under low AFP (≤ 20 ng/mL). The aim of this study was to elucidate the role of AFP‐L3 in HCC patients with low AFP conditions.


Alimentary Pharmacology & Therapeutics | 2010

Evolution of prognostic factors in hepatocellular carcinoma in Japan

Kazuhiro Nouso; Yoshiyuki Kobayashi; Shin Ichiro Nakamura; Sayo Kobayashi; Junichi Toshimori; Kenji Kuwaki; Hiroaki Hagihara; Hideki Onishi; Yasuhiro Miyake; Fusao Ikeda; Hidenori Shiraha; Akinobu Takaki; Yoshiaki Iwasaki; Haruhiko Kobashi; Kazuhide Yamamoto

Aliment Pharmacol Ther 31, 407–414


Endoscopy | 2013

Endoscopic submucosal dissection of esophageal cancer using the Mucosectom2 device: a feasibility study

Yoshiro Kawahara; Keisuke Hori; Ryuta Takenaka; Junichiro Nasu; Seiji Kawano; Masahide Kita; Takao Tsuzuki; Minoru Matsubara; Sayo Kobayashi; Hiroyuki Okada; Kazuhide Yamamoto

BACKGROUND AND STUDY AIMS Endoscopic submucosal dissection (ESD) is being increasingly used for superficial esophageal cancers. However, esophageal ESD is technically difficult, time consuming, and less safe compared with endoscopic mucosal resection (EMR). To perform ESD safely and more efficiently, various types of knives have been developed. This study compared the efficacy of our newly developed device, Mucosectom2, with that of conventional devices for esophageal ESD. PATIENTS AND METHODS Between May 2007 and February 2011, ESD was performed for 172 esophageal lesions. Of these, 120 lesions were treated by conventional devices only, whereas 52 lesions were treated by conventional devices and the Mucosectom2. Procedure time, en bloc and R0 resection rates, and adverse events were retrospectively compared between the conventional and Mucosectom2 groups. RESULTS The median procedure time was 48.0 minutes in the conventional group and 21.5 minutes in the Mucosectom2 group; the procedure time was significantly shorter in the Mucosectom2 group than in the conventional group (P < 0.0001). The en bloc and R0 resection rates were lower in the conventional group than those in the Mucosectom2 group, although these differences were not significant. The rate of exposure of the muscle layer in the Mucosectom2 group was significantly lower than in the conventional group (P = 0.04). The rates of perforation and postoperative bleeding were not significantly different between the two groups. CONCLUSIONS This feasibility study suggests that, compared with conventional ESD devices, the Mucosectom2 may decrease the time required for esophageal ESD. Although our groups appeared comparable, they were studied at different times. Endoscopic expertise and endoscope quality may have differed during these periods, thereby affecting the results of our study. A prospective trial is therefore required to confirm our results.


Hepatology Research | 2013

Serum oxidative–anti‐oxidative stress balance is dysregulated in patients with hepatitis C virus‐related hepatocellular carcinoma

Mamoru Nishimura; Akinobu Takaki; Naofumi Tamaki; Takayuki Maruyama; Hideki Onishi; Sayo Kobayashi; Kazuhiro Nouso; Tetsuya Yasunaka; Kazuko Koike; Hiroaki Hagihara; Kenji Kuwaki; Shinichiro Nakamura; Fusao Ikeda; Yoshiaki Iwasaki; Takaaki Tomofuji; Manabu Morita; Kazuhide Yamamoto

Oxidative stress is associated with progression of chronic liver disease (CLD). This association is best established in chronic hepatitis C. However, the anti‐oxidative state is not well characterized. The objective of the present study was to investigate the balance of oxidative and anti‐oxidative stress in CLD patients.


Journal of Gastroenterology and Hepatology | 2013

Prognotic impact of serum follistatin in patients with hepatocellular carcinoma

Takeshi Tomoda; Kazuhiro Nouso; Koji Miyahara; Sayo Kobayashi; Hideaki Kinugasa; Junki Toyosawa; Hiroaki Hagihara; Kenji Kuwaki; Hideki Onishi; Shinichiro Nakamura; Fusao Ikeda; Yasuhiro Miyake; Hidenori Shiraha; Akinobu Takaki; Kazuhide Yamamoto

Follistatin (FST) is a glycoprotein expressed in most organs, which interacts with activins or other members of the transforming growth factor beta family. Recently, several reports have shown that FST regulates a variety of processes during tumor progression. Here, serum FST in patients with liver diseases was measured, and its clinical utility as a biomarker was assessed.


Hepatology Research | 2012

Evaluation of the effect of sorafenib using serum NX‐des‐γ‐carboxyprothrombin in patients with hepatocellular carcinoma

Koji Miyahara; Kazuhiro Nouso; Yuki Morimoto; Takeshi Tomoda; Sayo Kobayashi; Yasuto Takeuchi; Hiroaki Hagihara; Kenji Kuwaki; Hideki Ohnishi; Fusao Ikeda; Yasuhiro Miyake; Shinichiro Nakamura; Hidenori Shiraha; Akinobu Takaki; Kazuhide Yamamoto

Des‐γ‐carboxyprothrombin (DCP) is known to be increased by the use of sorafenib for the treatment of hepatocellular carcinoma (HCC), despite its therapeutic efficacy. In addition to the tumor progression, hypoxia that impairs vitamin K uptake is known to induce DCP and this mechanism may explain DCP elevation by sorafenib. In this study, we tried to evaluate the effect of sorafenib treatment using a new marker, NX‐DCP, which is specific to vitamin K absence.


Cases Journal | 2009

A case of hepatocellular carcinoma with skin injury of the upper abdominal wall after transcatheter arterial chemoembolization: a case report

Hiromitsu Kanzaki; Kazuhiro Nouso; Koji Miyahara; Naoko Kajikawa; Sayo Kobayashi; Ichiro Sakakihara; Shota Iwadow; Shuji Uematsu; Ryoichi Okamoto; Kunihiro Shiraga; Motowo Mizuno; Yasuyuki Araki

IntroductionTranscatheter arterial chemoembolization has been widely used to treat advanced hepatocellular carcinoma that cannot be treated by local ablation therapies or surgical resection. The effectiveness of transcatheter arterial chemoembolization in prolonging survival has been well established, and approximately one third of newly discovered hepatocellular carcinoma patients were repeatedly treated by transcatheter arterial chemoembolization in Japan. Various kinds of complications have been reported, and many of which are general complications such as hepatic coma, jaundice, fever-up, ascites, and bile duct injury.The hepatic falciform artery is found frequently during postmortem anatomic dissection and the incidence of hepatic falciform artery is reported to be over 60%. Hepatic falciform artery is known to be the responsible artery for supraumbilical skin rash development after arterial chemo infusion therapy; however, skin complications after transcatheter arterial chemoembolization are rare.Case presentationA 70-year-old female with chronic hepatitis C infection was diagnosed as having hepatocellular carcinoma (S4, 20 mm in diameter). Transcatheter arterial chemoembolization was performed via the left hepatic artery, which was a feeding artery of the hepatocellular carcinoma. Two days after that, supraumbilical skin rash with local tenderness and redness appeared. Retrospective analysis revealed that occlusion of the hepatic falciform artery branching from the left hepatic artery with micromaterials caused the skin lesion.ConclusionWe should keep in mind that anticancer drugs or embolic materials can flow into the HFA and may cause abdominal wall injury after transcatheter arterial chemoembolization.

Collaboration


Dive into the Sayo Kobayashi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge